PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	09890335
Filing Date	2002-04-08
First Named Inventor	Cevc
Art Unit	1645
Examiner Name	B.J. Gangle
Attorney Docket Number	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6448296	A1	2002-09-10	Yasueda et al.	
	2	6451339	A1	2002-09-17	Patel et al.	
	3	6562370	A1	2003-05-13	Luo et al.	
	4	6582724	A1	2003-06-24	Hsu et al.	
	5	6586000	A1	2003-07-01	Luo et al.	
	6	6645520	A1	2003-11-11	Hsu et al.	
	7	6645529	A1	2003-11-11	Gergely et al.	
	8	6726598		2004-04-27	Jarvis et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

	9	6835392	A1	2004-12-28	Hsu et al.	
	10	RE33273		1990-07-24	Speaker	
	11					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	93/19737	WO		1993-10-14	Kabi Pharmacia AB		☐
	2	05/063213	WO		2005-07-14	Biodelivery Sciences International, Inc.		☐
	3	95/09831	WO		1995-04-13	Nicox Ltd. et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

	4	06/050926	WO		2006-05-18	IDEA AG		☐
	5	02/32398	WO		2002-04-25	Massachusetts Institute of Technology		☐
	6	98/33483	WO		1998-08-06	Depotech Corporation		☐
	7	93/19736	WO		1993-10-14	Kabi Pharmacia AB		☐
	8	01/01962	WO		2001-01-11	IDEA Innovative GmbH		☐
	9	90/11065	WO		1990-10-04	Theratec, Inc.		☐
	10	00/13684	WO		2000-03-16	Loma Linda University Medical Center		☐
	11	94/26257	WO		1994-11-24	LTS Lohmann Therapie-Systeme GmbH & Co.		☒
	12	00/12060	WO		2000-03-09	Cevc		☐
	13	92/05771	WO		1992-04-16	Kabi Pharmacia		☐
	14	99/22703	WO		1999-05-14	Lurident Ltd.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	Karzel and R.K. Liedtke, "Mechanism Transkutaner Resorption," on Grundlagen/Basics, pp. 1487-1491	☒
	2	Katoulis et al., "Efficacy of a new needleless insulin delivery system monitoring of blood glucose fluctuations and free insulin levels," on International J. of Artificial Organs 12(5):333-338 (1989)	☐
	3	Klibanov, et al., "Activity of amphipathic poly(ethylene gycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target," BBA 1062:142-148 (1991)	☐
	4	Knepp et al., "Controlled drug release from a novel liposomal delivery system II. Transdermal delivery characteristics," J. Contr. Release 12(1):25-30 (Mar. 1990) Amsterdam, NL	☐
	5	Lasch, J. et al., "Interactions of external lipids (lipid vesicles) with the skin" J. Liposome Research 5(3):543-569 (1995)	☐
	6	Lehmann, J. et al., "Analgesic and anti-inflammatory efficacy of IDEA-070 in UVB-induced sunburn." J. Eur. Acad. Dermatol. Venereol. 18(S2):267-268 (Oct. 2004)	☐
	7	Litchenberg, D. et al., "Solubilization of phospholipids by detergents: structural and kinetic aspects" BBA 737:285-304 (1983)	☐
	8	Lobbecke, et al., "Effects of short-chain alcohols on the phase behavior and interdigitation of phosphatidylcholine bilayer membranes" BBA 1237:59-69 (1995)	☐
	9	Mayer, L.D. et al., "Vesicles of variable sizes produced by a rapid extrusion procedure," BBA 858:161-168 (1986)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

	10	Merck Index: 10th Edition. 1983. Pages 779-780.	☐
	11	Mezei, "Liposomes as a skin drug delivery system," 1985 Elsevier Science Publishers B.V. (Biomedical Division) pp.345-358	☐
	12	Ogiso, Taro et al., "Membrane-controlled transdermal therapeutic system containing clonazepam and anticonvulsant activity after its application." Chem. Pharm. Bull. 37(2):446-449 (1989)	☐
	13	Patel, H.M. et al., "Oral administration of insulin by encapsulation within liposomes," FEBS Letters 62(1):60-63 (Feb. 1976)	☐
	14	Patel, H.M., "Liposomes as a controlled-release system," Biomedical Society Transactions 609th Meeting, Leeds, pp.513-516.	☐
	15	Peters, et al., "Pharmacodynamics of a liposomal preparation for local anaeshesia," Arzneim-Forsch/Drug Res. 45(II), Nr12 (1995), pages 1253-56	☐
	16	Planas, et al., "Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes," Anesth. Analg. 75:615-621 (1992)	☐
	17	Price, C.E., "A review of the factors influencing the penetration of pesticides through plant leaves," on I.C.I. Ltd., Plant Protection Division, Jealott's Hill Research Station, Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252	☐
	18	Product Information: "Polysorbate 80 VG" (2004)	☐
	19	Product Information: "Tween 80 Pure" (2004)	☐
	20	Prof. Dr. K-U Benner, Der Korper des Menschen, "The human body" Weltbild GmbH Augsburg Chapter 4 page 49 (1995)	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

	21	Ranade V., "Drug delivery systems. 6. Transdermal drug delivery," J. Clin. Pharmacol. 31:401-418 (1991)	☐
	22	Roeding, J. "Liposomes and niosomes in pharmacy and cosmetics state of art prospects, techniques of visualizing vesicular systems, interaction of liposomes with the skin" Training course no. 105 from May 14-16, 1990. Maritim Hotel Nurnberg, Frauentorgraben 11, 8500, Nurnberg.	☐
	23	Schramlova, J. et al., "The effect of an antiphlogisitic incorporated in liposomes on experimentally induced inflammation," Fola Biologica (Praha) 43:195-199 (1997)	☐
	24	Schreier, H. "Liposomes - A novel drug carrier. I. Phospholipids; production and characterization of liposomes; II. Destiny of liposomes in vivo; use in therapy," Pharmazie in unserer Zeit, No. 4 (1982)	☐
	25	SERVA Feinbiochyemica, Katalog, pages 201-202 (1986/1987)	☐
	26	Siddiqui, O. et al., "Nonparenteral administration of peptide and protein drugs," CRC Critical Review in Therapeutic Drug Carrier Systems, Vol. 3, Issue 3 pg. 195-208	☐
	27	Stoye, I. et al., "Transformation of a liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - physico-chemical characterization and influence on drug permeation through excised human stratum corneum," Eur. J. Pharmaceuticals and Biopharmaceuticals 46:191-200 (1998)	☐
	28	Swenson, E. Scott and William J. Curatolo, "Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity" Advanced Drug Delivery Reviews, 8:39-92 (1992)	☐
	29	Trotta, M. et al., "Deformable liposomes for dermal administration of methotrexate," International J. of Pharmaceutics (Kidlington) 270(1-2) 11 Feb 2004, pages 119-125	☐
	30	Trotta, M. et al., "Elastic liposomes for skin delivery of dipotassium glycyrrhizinate," International J. of Pharmaceutics (Kidlington) 241(2) 25 Jul 2002, pages 319-327	☐
	31	Valenta, C. et al, "Evaluation of novel soya-lecithin formulations for dermal use containing ketoprofen as a model drug," J. Contr. Release 63:165-173 (2000)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

	32	Vinggaard, A.M., et al., "Didecanoyl phosphatidylcholine is a superior substrate for assaying mammalian phospholipase D." Biochem. J. 319:861-864 (1996)	☐
	33	Vinson, P. et al., "Vesicle-micelle transition of phosphatidylcholine bilayers and octylglucoside elucidated by cryo-transmission electron microscopy," Biophys. J., Biophysical Society Vol. 56, October 1989 pages 669-681.	☐
	34	Vyas et al., "Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery," J. Microencapsulation, 1995, 12(2):149-154.	☐
	35	Wearley LL, "Recent progress in protein and peptide delivery by noninvasive routes." Crit. Rev. Ther. Drug Carrier Syst. 8:331-94 (1991)	☐
	36	Wess, L.: "All in the Family." Biocentury, the Bernstein Report on Biobusiness, 12(22):A11-A12 17 May 2004 (2004-05-17)	☐
	37	Yuan, et al., "Cationic liposome and gene transfer," Progress in Physiological Science, 28(2): 163-165 (1997) (English translation only)	☒
	38	Jackson, M.L. et al., "Solubilization of phosphatidylcholine bilayers by octyl glucoside" Biochemistry 21:4576-4582 (1982)	☐
	39	English language abstract of EP 0 298 280 A from Derwent	☐
	40	English language abstract of EP 0 102 324 from Derwent	☐
	41	Pierson et al., "Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents" J. Med. Chem. 40:4302-07 (1997)	☐
	42	Lee et al., "Intranasal bioavailability of insulin powder formulations: Effect of permeation enhancer-to-protein ratio" J. Pharm. Sci. 80(8):725-29 (1991)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	09890335
	Filing Date	2002-04-08
	First Named Inventor	Cevc
	Art Unit	1645
	Examiner Name	B.J. Gangle
	Attorney Docket Number	

	43	Shao et al., "Cyclodextrins as nasal absorption promoters of insulin: Mechanistic evaluations" Pharm. Res. 9 (9):1157-63 (1992)	☐
	44	Illum et al., "Chitosan as a novel nasal delivery system for peptide drugs" Pharm. Res. 11(8):1186-89 (1994)	☐
	45	Lowell et al., "Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG" J. Infect. Dis. 175:292-301 (1997)	☐
	46	Schreier et al., "Liposomen - ein neuartiger Arzneist offtrager II. Schicksal von Liposomen in vivo: Einsatz in der Therapie", Pharmazie in unserer Zeit No. 4 (1982), pages 103-108	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.